• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 20th July 2010

Part 1: 2010 Lecture on US Health Reform

Each year, OHE sponsors an Annual Lecture that examines an important issue in health care. In late June, Dr Alan Garber spoke on US health care reform. This is the first of two posts that summarises his remarks. It reviews…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
garber2_7-15-10

Each year, OHE sponsors an Annual Lecture that examines an important issue in health care. In late June, Dr Alan Garber spoke on US health care reform. This is the first of two posts that summarises his remarks. It reviews the background for and the intent of the new legislation signed into law in March 2010.

OHE annually sponsors a lecture that examines an important issue in health care. This year’s speaker was Dr Alan Garber, Director both of Stanford University’s Center for Health Policy and its Center for Primary Care and Outcomes Research at the School of Medicine.  His presentation, ‘US Healthcare Reform: Monumental Health System Transformation or Fatally Flawed Compromise?’, is summarised in two blog posts.  The first of these follows.

Attempts at health care reform in the US have a long and varied history.  Before the current legislation, the most important health reform was legislation signed in 1965 that created Medicare, which provided insurance for those 65 years of age and older, and Medicaid, which insured the indigent.  Attempts in the early 1990s to implement universal health insurance failed, with significant political repercussions.  That experience, coming shortly after the repeal of a less ambitious piece of legislation, the Medicare  Catastrophic Coverage Act, discouraged politicians from taking up health reform for many years.

Dr Garber noted that three factors encouraged the Obama Administration and Congress to once again attempt major reform: (1) barriers to access to care for the large uninsured population (46 million in 2008)[1], (2) a perceived ‘value deficit’ as expenditures for care were rising rapidly without evidence of commensurate health improvements and (3) concerns about the impact on the federal budget of rising costs for certain programmes, particularly Medicare.

Support for health reform, however, was soft and attempts to pass legislation were politically risky, Dr Garber noted.  Despite concerns about costs and access, the general public did not place health care reform as high on its list of concerns as it did other matters – specifically, the economy and jobs, the solvency of Medicare and Social Security (the retirement fund), and reducing the budget deficit.  Although most Democrats favoured health reform, opposition from some quarters was very strong; the road to passage of the legislation was rocky, with many surprises appearing along the way.

What the Patient Protection and Affordable Care Act is intended to accomplish

According to the nonpartisan Congressional Budget Office, 32 million of the 36 million non-elderly, legal residents who now are uninsured should become insured over the next ten years[2].  This means that 94% of that population will be insured.

Under the legislation, the federal government will spend $930 billion over ten years.  This includes $358 billion to (1) subsidize the purchase of insurance by Americans at the lower end of the income spectrum, but above the levels required to receive Medicaid and (2) support and oversee ‘insurance exchanges’ to ensure that affordable insurance is available to individuals and small businesses.  $106 billion will be spent on ‘re-insurance’ payments (a form of risk adjustment) to more evenly spread the risk of high-cost plan members across insurers.  SCHIP, a government insurance programme for children, and Medicaid will receive $434 billion. The remaining spending is allocated to a variety of other programmes.

Since Congress strives for budget neutrality in its legislation, it also had to identify areas of savings that could counterbalance these expenditures.  This included a $455 billion reduction in expenditures in government health programmes, $107 billion additional income from fees from manufacturers and insurers, and $210 billion from an increase in the tax on personal income that supports Medicare hospital expenditures.  All in all, the legislation was expected to reduce the federal government’s budget deficit by $124 billion over ten years.

According to Dr Garber, what the expenditures and changes in programmes are meant to achieve is: (1) protection for buyers in health insurance markets, thus increasing access to insurance, (2) changing incentives for the provision of care in both private and government programmes by adjusting payment metrics, (3) emphasizing prevention and primary care and (4) encouraging health care providers — particularly physicians and hospitals – to work more closely together, reducing costs by better integrating care.  The overall objective is more effective, efficient care.

The second post will appear shortly; the full text of Dr Garber’s lecture now is available as part of the OHE Annual Lecture series.


[1] Lack of insurance does not mean that no care is received, as people outside the US often assume.  For example, federal laws and some state laws mandate some care for the uninsured; providers also often provide charity care; nonprofits and state or local governments provide free clinics, and other means of access of are available.  However, access for the uninsured often is not timely or consistent and is restricted. [2] See the CBO Director’s Blog: http://cboblog.cbo.gov/?p=546

  • Healthcare Systems
  • Annual Lecture

Related News

MicrosoftTeams-image-6_0
  • News
  • June 2022

OHE’s 60th Anniversary Party – Celebrating Our Achievements and Looking Forward

Read more
  • News
  • June 2020

The 2020 OHE Annual Lecture Explores the Question: How Should the World Pay for a COVID-19 Vaccine?

Read more
  • News
  • January 2020

OHE Lunchtime Seminar: Personalised Medicine: Is it an oil-rush or oil-spill?

Read more
  • News
  • September 2019

OHE Lunchtime Seminar: Closing the ‘Know-do’ Gap for Health Systems Reform at the Policy Level

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!